MRNA-LNP vaccination-based immunotherapy augments CD8⁺ T cell responses against HPV-positive oropharyngeal cancer.

ABSTRACT: Although mRNA vaccines are known as potent activators of antigen-specific immune responses against infectious diseases, limited understanding of how they drive the functional commitment of CD8⁺ T cells in tumor microenvironment (TME) and secondary lymphoid organs hinders their broader application in cancer immunotherapy. Here, we systematically evaluated the immunological effects of a lipid nanoparticle (LNP)-encapsulated mRNA vaccine that encodes human papillomavirus E7 protein (HPV mRNA-LNP), a tumor-specific antigen of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). HPV mRNA-LNP vaccination activated overall and HPV-specific CD8⁺ T cells, as well as differentially drove the functional commitment of CD8⁺ T cells through distinct IFN-response a

SUBMITTER: Qiu K 

PROVIDER: S-EPMC10542330 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature